Table 6 Adverse events occurring in at least 5% of patients considered to be possibly related to treatment
Adverse events (% of patients) | ||
|---|---|---|
Cilengitide + Gemcitabine n = 44 | Gemcitabine n = 42 | |
Nausea | 36% | 38% |
Leukopenia | 36% | 26% |
Thrombocytopenia | 34% | 33% |
Anemia | 27% | 26% |
Fatigue | 23% | 19% |
Vomiting | 18% | 26% |
Fever | 11% | 10% |
Shivering | 14% | 2% |
Peripheral edema | 9% | 5% |
Headache | 9% | 0% |
Sweating increased | 11% | 2% |
Asthenia | 7% | 10% |
Edema | 7% | 5% |
Dyspepsia | 7% | 7% |
Anorexia | 7% | 14% |
Hair changes | 5% | 12% |